Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

IBRUTINIB

IBRUTINIB

Standard Dose
280MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview IBRUTINIB is listed in Drugs@FDA under application 215464 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient IBRUTINIB Form and strength TABLET;ORAL - 280MG Sponsor SANDOZ INC Submission history Latest submission status date: 2023-02-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview IBRUTINIB is listed in Drugs@FDA under application 215464 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient IBRUTINIB Form and strength TABLET;ORAL - 280MG Sponsor SANDOZ INC Submission history Latest submission status date: 2023-02-10 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.